Adicet Bio (ACET) Cash from Operations (2017 - 2026)
Adicet Bio (ACET) posted quarterly Cash from Operations of 21490000.0 for Q1 2026, up 15.38% year-over-year from 18624813.34 in Q1 2025, and down 2.78% quarter-over-quarter from 20909000.0 in Q4 2025.
Adicet Bio (ACET) Cash from Operations (2017 - 2026) Analysis & Trends
Adicet Bio's Cash from Operations history runs 10 years deep, the most recent figure standing at 21490000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 15.38% year-over-year to 21490000.0; the TTM figure through Mar 2026 stood at 91339000.0 (up 3.78% YoY), while the FY2025 annual figure was 95246000.0, down 3.1% from the prior year.
- Cash from Operations for Q1 2026 stood at 21490000.0, down from 20909000.0 in the prior quarter.
- The five-year high for Cash from Operations was 4105000.0 in Q1 2022, with the low at 26633000.0 in Q2 2025.
- The 5-year median for Cash from Operations is 22307000.0 (2025), against an average of 20446823.53.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations soared 127.1% in 2022, then tumbled 686.94% in 2023.
- Adicet Bio's Cash from Operations stood at 18837000.0 in 2022, then dropped by 24.68% to 23486000.0 in 2023, then fell by 2.62% to 24101000.0 in 2024, then gained by 13.24% to 20909000.0 in 2025, then slipped by 2.78% to 21490000.0 in 2026.
- Business Quant data shows ACET's Cash from Operations at 21490000.0 in Q1 2026, 20909000.0 in Q4 2025, and 22307000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 728.46 Mn |
| 10 | Adicet Bio | 101.13 Mn | -17.06 Mn | - | -19.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.82 Mn |
| Jun 30, 2026 | -19.82 Mn |
| Mar 31, 2026 | -21.49 Mn |
| Mar 31, 2026 | -21.49 Mn |
| Dec 31, 2025 | -20.91 Mn |
| Dec 31, 2025 | -20.91 Mn |
| Sep 30, 2025 | -22.31 Mn |
| Sep 30, 2025 | -22.31 Mn |
| Jun 30, 2025 | -26.63 Mn |
| Jun 30, 2025 | -26.63 Mn |
| Mar 31, 2025 | -25.40 Mn |
| Mar 31, 2025 | -25.40 Mn |
| Dec 31, 2024 | -24.10 Mn |
| Dec 31, 2024 | -24.10 Mn |
| Sep 30, 2024 | -22.01 Mn |
| Sep 30, 2024 | -22.01 Mn |
| Jun 30, 2024 | -23.42 Mn |
| Jun 30, 2024 | -23.42 Mn |
| Mar 31, 2024 | -22.85 Mn |
| Mar 31, 2024 | -22.85 Mn |